Astherna

Astherna stands as a cutting-edge RNA therapy company, with a devoted team of specialists focused on treating retinal disorders through antisense oligonucleotides. We target previously untreated conditions, such as Stargardt disease and USH2A-associated retinal disease, with the aim to meet the urgent needs of a global community with hundreds of thousands of affected individuals. At Astherna, our mission is clear: prevent blindness and offer effective therapeutic innovations for these challenging disorders. We are committed to accelerating the journey from bench to clinical application, all while ensuring our pipeline prioritizes both efficacy and safety to maximize positive impacts on patients’ lives.